Noble Life Sciences is a contract research organisation (CRO) providing good laboratory process (GLP) and non-GLP in-vivo and in-vitro animal models for research and development (R&D) programmes.
The company’s preclinical development services offer efficient and adaptable development approaches to drug, medical device and vaccine-developing pharmaceutical and biotechnology companies, as well as research institutes. The testing services include pharmacology, toxicology, disease models, analytical testing, safety assessments and cell line development.
Noble Life Sciences helps address some of the most prominent challenges of preclinical research, including procuring high-quality animal services. These solutions meet the requirements of the office of Laboratory Animal Welfare (OLAW) and the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), and the firm also holds a US Department of Agriculture (USDA) licence.
The company has extensive experience in testing medical devices for efficacy and safety in the areas of orthopaedic, cardiovascular, trauma and wound healing.
Cardiovascular models for preclinical development
Noble Life Sciences has a comprehensive range of cardiovascular testing models and understands the unique challenges of interventional cardiology programmes.
The company’s state-of-the-art equipment supports investigations into cardiovascular disease and injury with services such as acute myocardial infarction, peripheral arterial disease and thrombosis models; heart valve and electrostimulation studies; venous and arterial grafts; cardiac assist and in-vivo heart capture devices; cell therapies; Langendorff working heart perfusion stand; and prototype evaluations.
Orthopaedics devices and implant testing
Noble Life Sciences tests orthopaedic devices and implants for applications such as osteoarthritis, arthroplasty and cartilage repair, anterior cruciate ligament (ACL) repair, artificial meniscus, reconstruction and fixation of ligaments and tendons, and osteotomy of the femur, tibia and radius, as well as posterior lumbar interbody fusion (PLIF).
Models for response to physical trauma
Noble Life Sciences’ medical device division utilises innovative equipment to support investigations into how the body responds to physical trauma and the recovery process.
The company’s high-quality, flexible and customised trauma testing services are suitable for critical care training programmes.
Wound healing and care solutions
Noble Life Sciences provides wound healing testing devices and therapies that improve the efficiency and efficacy of the body’s response to trauma or injury.
The company provides a wide range of solutions, including:
- Skin grafts
- Burn models
- Diabetic models
- Full-thickness excisional and incisional wounding and repair analysis
- Stem cell, individual patient solutions (IPS) and multipotent stromal cell (MSC) implantation models
- Electrostimulation models
- Motility assays (fluorescence and light microscope)
- Scar tissue tensile strength analysis and histology
- Interstitial fluid collection and analysis
- Nutritional and pharmaceutical supplementation
Analytical and laboratory services
Noble Life Sciences provides analytical and laboratory services, comprising cell-based, gene-expression, clinical pathology and customised assays.
Available cell-based assays include cell cytotoxicity, proliferation, apoptosis, viability, transmigration, wound healing and cell line screening assays.
The company’s in-house scientists are experts in designing high-throughput quantitive polymerase chain reaction (qPCR) assays and gene expression microarrays, as well as monitoring biomarker expression in animal models and tracking gene panel and pathway markers.
Imaging solutions for medical devices
Noble Life Sciences provides an array of imaging solutions, including:
- Live animal imaging with the Perkin Elmer IVIS system, which uses bioluminescent or fluorescent reporters
- C-arm imaging scanner intensifier with radiographic capabilities for animal model imaging
- Computed tomography (CT) 32 and 64-slice
- Magnetic resonance imaging (MRI) 1.5T and 3T scanners
About Noble Life Sciences
Noble Life Sciences conducts high-quality research to advance human health and facilitate personalised medicine.
The company’s highly experienced consulting surgeons include Christopher C. Kwon, Peter W. Cho and Harold Aberman.
Kwon is chief of cardiovascular surgery. He specialises in transcatheter aortic valve replacement (TAVR), endovascular therapies for thoracic and abdominal aortic diseases and transcatheter therapies for structural heart disease. He has published and lectured on TAVR, having completed his Doctorate at the Albert Einstein College of Medicine in New York, US. He was previously chief of cardiothoracic and endovascular surgery at Havasu Regional Medical Center.
Cho specialises in heart valve repair, aortic reconstruction, TAVR and the Maze procedure. He spent two years in the cardiac surgery research laboratories of the Johns Hopkins Hospital, conducting studies using animal models of cardiovascular disease. He has also published a wide range of publications and holds a patent for a cavo-atrial cannula for cardiopulmonary bypass.
Aberman is a consulting surgeon with more than 25 years of experience in the medical device industry. He specialises in the development and testing of medical devices, particularly orthopaedic units. His previous positions include the Global Scientific Programme director and director of non-fusion product development for DePuy Synthes.